Developer of treatments for neuromuscular and neuro-ophthalmological diseases Santhera Pharmaceuticals has hired Kristina Sjöblom Nygren as Chief Medical Officer and Head of Development.
Belgian ViroVet NV, which develops vaccines and antiviral drug for livestock, has named George Gunn as the newest member of its board of directors. Until early 2015, Gunn was CEO of Novartis Animal Health and a member of the global executive committee of Novartis.
Promega-founder William Linton has been elected as a member of the Supervisory Board of lab supplier Eppendorf AG.
London-based brain health company Ixico has hired Giulio Cerroni as its new Chief Executive Officer. Cerroni replaced co-founder Derek Hill, who will remain on the board and serve as executive director going forward.
Mithra Pharmaceuticals, a Belgian company focused on women’s health, has appointed Christophe Maréchal as Chief Financial Officer.
Swiss rare genetic diseases company Therachon AG has named Luca Santarelli Chief Executive Officer and Director. Santarelli brings widespred experience from his role as Venture Partner at Versant Ventures, founding investor of Therachon.
Malte Peters will leave Sandoz to take over as Chief Development Officer of Morphosys AG. Peters succeeds Arndt Schottelius, who held the position for eight yeara.
Novozymes company Albumedix A/S has appointed Giles Campion new Chief Medical Officer. Campion will be in charge of leading the development efforts of the Danish leader in albumin-based drug delivery.
Milan-based Newron Pharmaceuticals has named Dennis Dionne Vice President Commercial Affairs. Previously, Dionne was Executive Director for Commercial Operations. He replaces Anders Haegerstrand.
Deborah Waterhouse, currently Senior Vice President Primary Care, GSK US Pharmaceuticals, will take over as CEO of Viiv Healthcare. She succeeds Dominique Limet, who will step down from the post at the end of March 2017.